Long-term cocaine use is a risk factor for the onset of neurocognitive impairment. This study sought to determine whether the cholinesterase inhibitor rivastigmine could improve neurocognitive performance in cocainedependent individuals. Cocaine-dependent individuals who were not seeking treatment at the time of enrollment in the study were randomly assigned to receive placebo (n = 16), rivastigmine 3 mg (n = 13), or rivastigmine 6 mg (n = 12). The baseline neurocognitive assessment, which included measures of attention/ information processing (as measured by the Continuous Performance Task-II (CPT-II)), verbal learning/episodic memory (as measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)), and working memory (as measured by the Dual N-Back Task), was conducted prior to the administration of study medication (Day 0). The follow-up assessment was conducted on Day 8 after the participants had received rivastigmine or placebo for 7 days (Day 2-8). Rivastigmine administration significantly improved performance on one measure of working memory span (mean n-back span). This study provides additional data showing that cocaine-associated neurocognitive impairment, specifically working memory deficits, can be remediated, at least to some degree.
Background/introduction
Previous studies have reported that sustained cocaine use may result in neurocognitive impairment in humans (Bolla and Cadet, 2007; Jovanovski et al., 2005) . Specifically, a meta-analytic review revealed effect sizes of moderate or greater magnitude in the domains of attention, episodic memory, and working memory (Jovanovski et al., 2005) . These neurocognitive impairments may have detrimental consequences for cocaine-dependent individuals as they attempt to maintain successful daily functioning; for example, the presence of cocaine related neurocognitive deficits have been reported to be associated with poor treatment retention (Aharonovich et al., 2003 (Aharonovich et al., , 2006 (Aharonovich et al., , 2008 Sofuoglu, 2010) .
Since cocaine-associated neurocognitive impairments adversely affect important outcomes for cocaine addicts, then an important area of research involves whether stimulant-induced neurocognitive impairment can be reversed or ameliorated by using cognition enhancing interventions. Recent publications suggest that such improvements are feasible. For example, following of 20 mg of oral methylphenidate (a medication used to enhance cognitive functioning in individuals with attention deficit/hyperactivity disorder), cocaine-dependent individuals made fewer errors on a computerized cognitive salience task (in which participants viewed a drug-related or neutral word on a screen written in blue, green, red, or yellow font, then pressed the matching colored button on a key pad) (Goldstein et al., 2010) . Also, a recent study by our group revealed that modafinil (200 mg/day for 3 days) improved working memory in cocaine-dependent individuals, as measured by using a computerized n-back test (Kalechstein et al., 2013) .
One class of medications that has demonstrated an indication for the reversal of neurocognitive impairment are acetylcholinesterase (AChE) inhibitors. Treatment with AChE inhibitors, acetylcholine (ACh) precursors, or cholinergic agonists can improve learning and memory in animals (Hasselmo and Sarter, 2011) , healthy human subjects (Repantis et al., 2010) , and in patients with Alzheimer's disease and other neuropsychiatric disorders (Feldman and Lane, 2007; Frankfort et al., 2007) . Specifically, in double-blind, placebocontrolled studies, rivastigmine improved performance on tests of attention and memory in individuals diagnosed with Alzheimer's disease (Feldman and Lane, 2007; Frankfort et al., 2007) . Furthermore, in samples of individuals diagnosed with traumatic brain Progress in Neuro-Psychopharmacology & Biological Psychiatry 50 (2014) 137-142 
